Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Logo

The stock of Inovio Pharmaceuticals Inc (NASDAQ:INO) registered a decrease of 14.71% in short interest. INO’s total short interest was 11.74 million shares in December as published by FINRA. Its down 14.71% from 13.76M shares, reported previously. With 1.09 million shares average volume, it will take short sellers 11 days to cover their INO’s short positions. The short interest to Inovio Pharmaceuticals Inc’s float is 13.16%.

The stock increased 2.36% or $0.055 during the last trading session, reaching $2.385. About 1.02M shares traded or 46.04% up from the average. Inovio Pharmaceuticals, Inc. (NASDAQ:INO) has declined 32.02% since December 8, 2018 and is downtrending. It has underperformed by 32.02% the S&P500.

Inovio Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases. The company has market cap of $238.52 million. The Company’s SynCon immunotherapy design has the ability to break the immune systemÂ’s tolerance of cancerous cells; and SynCon product design is also intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza. It currently has negative earnings. It has completed, current or planned clinical programs of its proprietary SynCon immunotherapies for HPV-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus, hepatitis B virus, HIV, Ebola, Middle East Respiratory Syndrome, and Zika virus.

More notable recent Inovio Pharmaceuticals, Inc. (NASDAQ:INO) news were published by: which released: “Milacron Holdings (MCRN) Misses Q3 Earnings and Revenue Estimates – Nasdaq” on November 12, 2019, also with their article: “Inovio Pharma To Present At Piper Jaffray Conference; Webcast At 12:30 PM ET – Nasdaq” published on December 04, 2019, published: “Better Buy: Novavax vs. Inovio Pharmaceuticals – The Motley Fool” on November 26, 2019. More interesting news about Inovio Pharmaceuticals, Inc. (NASDAQ:INO) were released by: and their article: “INO: Great Things Take Time, And Now’s the Time – Yahoo Finance” published on November 04, 2019 as well as‘s news article titled: “Inovio Pharmaceuticals (INO) Reports Q3 Loss, Misses Revenue Estimates – Nasdaq” with publication date: November 12, 2019.

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Source link